<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159275</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 085</org_study_id>
    <nct_id>NCT01159275</nct_id>
  </id_info>
  <brief_title>Lopinavir (LPV) Dose Reduction</brief_title>
  <official_title>Pharmacokinetics of Pediatric Aluvia速 (Lopinavir /Ritonavir 100/25 mg) and Generic Lopinavir/Ritonavir Tablet Formulation (200/50 mg) in Clinically and Virologically Stable HIV-1 Infected Thai Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the pharmacokinetics profiles of generic
      lopinavir/ritonavir and Pediatric Aluvia速 at reduced dose by assessing safety, tolerability
      and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, 2 arms, randomized intensive PK study with cross over design. This
      design will provide us optimal information to answer our research question. First and most
      important, we can assess the PK when lopinavir/r is used in a dose reduced form. By
      randomizing the patients to either Abbott's pediatric Aluvia dose reduction or India generic
      LPV/r dose reduction will allow us to assess the differences in AE severity and frequency.
      Using the standard abbott product as a control our study will provide important information
      about the bioavailability of the generic product. Although it's not an original BE design we
      must be able to make preliminary comparisons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC, Cmin, Cmax of LPV/r between Aluvia and generic</measure>
    <time_frame>week 2</time_frame>
    <description>AUC, Cmin, Cmax of LPV/r between Aluvia and generic</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First Pediatric Aluvia速 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic LPV/r and Aluvia (pharmacokinetics)</intervention_name>
    <description>Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aluvia and Generic LPV/r (pharmacokinetics)</intervention_name>
    <description>First Pediatric Aluvia速 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Evidence of HIV infection (confirmed positive ELISA and/or documented history of
             measurable HIV RNA)

          3. Age&gt; 18 years

          4. Have been on standard dose of any PI containing regimen for at least 4 weeks prior to
             study entry

          5. Currently having no AIDS defining illness

          6. Plasma HIV RNA &lt; 50 copies/mL for at least 24 weeks

          7. Willing to adhere to the protocol requirements

        Exclusion Criteria:

          1. Any history of taking CYP450 inhibitors or inducers, or any gastric acid-reducing
             drugs within 14 days of enrollment in the study

          2. Current pregnancy or lactating

          3. Active opportunistic infection

          4. ALT/ AST more than 2x upper limit

          5. creatinine more than 1.5 time the upper limit

          6. Relevant history or current condition, illness that might interfere with drug
             absorption, distribution, metabolism or excretion

          7. History of sensitivity/idiosyncrasy to the drug or chemically related compounds or
             pharmaceutical excipients which may be employed in the study.

          8. Active drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anchalee Avihingsanon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>July 8, 2010</last_update_submitted>
  <last_update_submitted_qc>July 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anchalee Avihingsanon</name_title>
    <organization>HIV-NAT</organization>
  </responsible_party>
  <keyword>lopinavir/ritonavir</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>HIV-1 infected adults</keyword>
  <keyword>aim to investigate the lower dose of boosted lopinavir in Thais and to compare the levels of lopinavir/ritonavir from Abbot and GPO</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

